Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review

• DOI: 10.3389/fonc.2022.1016320
• Publication Date: 2022-10-17T07:43:18Z
• Authors: Dan Han; Kewei Zhao; Qin Yang; Liling Zhang; Shihong Fei
• Keywords: Pituitary Tumors

Background Pituitary metastasis accounts for a very low percentage of cases brain from lung cancer, and there are uncertainties challenges in diagnosis treatment. We hope to shed some light on the treatment by reporting case ALK fusion mutation-positive cancer pituitary metastasis. Case presentation report 48-year-old female patient with an initial stage IVB adenocarcinoma fusion. The developed headache, dizziness, hypopituitarism hyperprolactinemia one year after crizotinib. Later, underwent neurosurgical resection tumor then symptomatic relief. Postoperative pathology suggested metastasis, next-generation gene sequencing conducted indicated that secondary drug resistance mutation ALK-I1171s occurred gene. Conclusion In this article, we present suspected metastases cancer. progression mass suggestive further